Holen Sie sich die Stockscreener-App
13.61
1.11%
0.15
Handel nachbörslich:
13.50
-0.11
-0.81%
Schlusskurs vom Vortag:
$13.46
Offen:
$13.03
24-Stunden-Volumen:
38,597
Relative Volume:
0.01
Marktkapitalisierung:
$14.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.13M
KGV:
-0.0397
EPS:
-342.9759
Netto-Cashflow:
$-2.63M
1W Leistung:
-0.58%
1M Leistung:
+9.49%
6M Leistung:
+122.39%
1J Leistung:
-98.82%
1-Tages-Spanne:
$13.03
$14.25
1-Wochen-Bereich:
$11.79
$14.25
52-Wochen-Spanne:
$2.88
$2,235.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
13.61 | 14.02M | 0 | -1.13M | -2.63M | -342.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
PLRZ Should I Buy - Intellectia AI
Polyrizon reports nasal deposition study results for naloxone By Investing.com - Investing.com Australia
Polyrizon reports nasal deposition study results for naloxone - Investing.com
Polyrizon Reports Superior Nasal Deposition for Naloxone Formulation in Comparative Study - TipRanks
Polyrizon (Nasdaq: PLRZ) reports enhanced naloxone nasal deposition study - Stock Titan
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product - marketscreener.com
Lab test: Polyrizon nasal naloxone hits target area 94.6% vs 79.6% - Stock Titan
PLRZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
S&P 500 Gains 1%; April Jobs Top Expectations - Intellectia AI
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker - Yahoo Finance
Drug-free nasal spray NASARIX is designed to trap allergy triggers - Stock Titan
Polyrizon Ltd. announces $4.97 million securities offering - MSN
Polyrizon recives Nasdaq delisting notice - MSN
PLRZ Technical Analysis & Stock Price Forecast - Intellectia AI
Is Polyrizon Ltd. stock a value trapJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Polyrizon signs MOU to acquire 51% stake in Arrow Aviation By Investing.com - Investing.com South Africa
Polyrizon stock rises on potential acquisition of Arrow Aviation - Investing.com
Will Polyrizon Ltd. stock hit new highs in YEARQuarterly Trade Report & Smart Money Movement Tracker - mfd.ru
How Polyrizon Ltd. stock benefits from tech adoptionWeekly Stock Report & Weekly High Return Opportunities - mfd.ru
Polyrizon stock rises on potential acquisition of Arrow Aviation By Investing.com - Investing.com Canada
Polyrizon intends to secure controlling stake in profitable private jet operator - marketscreener.com
Polyrizon signs MOU to acquire 51% stake in Arrow Aviation - Investing.com
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator - The Manila Times
Biotech Polyrizon lines up $5.8M deal for $19M private jet firm - Stock Titan
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock: Partners With Polyrizon to Advance Intranasal MEAI Therapy - parameter.io
Polyrizon climbs on Clearmind Deal - Baystreet.ca
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal - Investing.com India
Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI - TipRanks
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation - The Manila Times
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Inc. Partners with Polyrizon Ltd. to Develop Innovative Intranasal Formulation for MEAI in CNS Disorders - Quiver Quantitative
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic ... - Caledonian Record
Biotechs team up on intranasal, non-hallucinogenic addiction therapy - Stock Titan
Polyrizon shares gain on plan to buy majority stake in private aviation company - MSN
Polyrizon Signs MOU to Acquire 51% Stake in Arrow Aviation - Intellectia AI
Polyrizon Moves to Acquire 51% Stake in Global Private Aviation Firm Arrow Aviation - TipRanks
Polyrizon stock rises after announcing plan to acquire stake in private aviation firm - Investing.com Nigeria
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company - The Manila Times
Biotech firm Polyrizon eyes $19M private jet business - Stock Titan
Aug Setups: Is Polyrizon Ltd stock a value trapDay Trade & Real-Time Volume Spike Alerts - baoquankhu1.vn
Polyrizon stock rises on FDA submission for PL-16 viral blocker - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):